Loading…
Study shows significant reduction in stress-induced behaviors in preclinical models.
Artelo Biosciences, Inc. announced on December 3, 2025, the publication of a new peer-reviewed study. The study demonstrates that intraperitoneal administration of a novel Fatty Acid Binding Protein 5 (FABP5) inhibitor significantly reduces stress-induced anxiety and depression behaviors in preclinical models.
The publication highlights the potential therapeutic benefits of the FABP5 inhibitor in treating anxiety and depression. The study's findings contribute to the growing body of research on novel treatments for mental health conditions.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.